Abstract | OBJECTIVE: CASE SUMMARY: A 50-year-old white, nonsmoking male with a history of hypertension, hyperlipidemia, paroxysmal atrial fibrillation, and hypothyroidism had been recently diagnosed with metastatic clear cell-type renal cell carcinoma. He was started on high-dose IL-2 therapy (600,000 IU/kg/dose by 15-min intravenous infusion every 8 h for up to 14 consecutive doses over 5 days, as tolerated). He developed new-onset LPFB after the second dose of IL-2, which was diagnosed electrocardiographically with right axis deviation; deep S waves in lead I; and qR waves in leads II, III, and aVF. He denied chest pain, palpitations, or syncope. The LPFB resolved 18 hours after discontinuation of IL-2 without any potential complications or delay of hospital discharge. The patient completed 9 of 14 doses of IL-2 therapy. Similar electrocardiogram changes were noticed during 2 subsequent cycles of high-dose IL-2 treatment, both of which resolved spontaneously. DISCUSSION: High-dose IL-2 is a Food and Drug Administration-approved biological agent used as monotherapy for the treatment of metastatic renal cell carcinoma and metastatic melanoma. Capillary leak syndrome has been associated with IL-2 therapy and many of its cardiac and noncardiac toxicities. In our patient, LPFB was observed as a reversible adverse reaction to high-dose IL-2 therapy. The Naranjo probability scale indicates a probable relationship between LPFB and high-dose IL-2 in this patient. LPFB has not previously been reported as an adverse reaction associated with high-dose IL-2 therapy. CONCLUSIONS: LPFB may be a reversible cardiac complication associated with high-dose IL-2 therapy. Healthcare professionals should be aware of this potential adverse effect.
|
Authors | Anand Singla, Samuel R Denmeade |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 42
Issue 9
Pg. 1340-3
(Sep 2008)
ISSN: 1542-6270 [Electronic] United States |
PMID | 18664608
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Adrenergic alpha-Agonists
- Antineoplastic Agents
- Interleukin-2
- Phenylephrine
|
Topics |
- Adrenergic alpha-Agonists
(therapeutic use)
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Bundle-Branch Block
(chemically induced)
- Humans
- Hypotension
(drug therapy)
- Interleukin-2
(administration & dosage, adverse effects, therapeutic use)
- Male
- Middle Aged
- Phenylephrine
(therapeutic use)
|